🇺🇸 mercaptopurine tablet in United States

10 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Acute Lymphocytic Leukaemia Recurrent — 1 report (10%)
  2. Alanine Aminotransferase Increased — 1 report (10%)
  3. Anger — 1 report (10%)
  4. Anxiety — 1 report (10%)
  5. Aspartate Aminotransferase Increased — 1 report (10%)
  6. Blood Bilirubin Increased — 1 report (10%)
  7. Blood Lactate Dehydrogenase Increased — 1 report (10%)
  8. Central Nervous System Leukaemia — 1 report (10%)
  9. Cerebral Haemorrhage — 1 report (10%)
  10. Condition Aggravated — 1 report (10%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is mercaptopurine tablet approved in United States?

mercaptopurine tablet does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for mercaptopurine tablet in United States?

National Cancer Institute (NCI) is the originator. The local marketing authorisation holder may differ — check the official source linked above.